“Patient Organizations Voice Their Views on the Priorities of an FDA Office of Patient Affairs”: Download Now
(June 2017) In response to an FDA request for input on a potential Office of Patient Affairs, Rx4good fielded a survey to ensure that a diverse group of patient advocacy organizations would be heard on this important topic. Findings from more than 200 patient groups include key insights into: a surprising lack of current patient engagement with the FDA, uncertainty about how to engage, patient groups’ significant interest in increased participation, and priority areas for patient engagement in the drug development process.
“Patients ultimately take these drugs. Shouldn’t they have a part in the decision-making process?”
“Developing trials that are effective for patients will increase enrollment and retention. Including clinically meaningful endpoints for patients will ensure that the therapies being developed have meaningful value. Engaging patients early will prevent trials that are of little value to patients being conducted.”